Microcap Ledger MAIA Biotechnology, Inc. $MAIA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Chicago, IL
- Fiscal year end
- December 31
- Shares outstanding
- 60,825,844 [10-Q 2026-08-10]
What the company doesAI summary of filing
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The company's lead asset is ateganosine (THIO), an investigational drug candidate that works by targeting telomeres and inducing immune responses; it is currently being tested in a Phase 2 clinical trial (THIO-101) in non-small cell lung cancer (NSCLC) patients in combination with checkpoint inhibitor cemiplimab, and a Phase 3 pivotal trial (THIO-104) was initiated in 2025. The company is pre-revenue and funds its operations through equity financing. MAIA plans to pursue additional Phase 2 trials in hepatocellular carcinoma, colorectal cancer, and small cell lung cancer, and is developing second-generation telomere-targeting compounds. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$14.31M | −$12.06M | $0.00 | [10-Q 2026-08-10] |
| FY ended Dec 2025 | — | −$22.40M | −$18.84M | $0.00 | [10-K 2026-03-23] |
| FY ended Dec 2024 | $0.00 | −$23.25M | −$15.70M | $0.00 | [10-K 2025-03-21] |
- Quarterly cash burn
- −$6.03M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 25,332,069 | [10-Q 2024-11-12] |
| 2025-03-21 | 29,587,314 | [10-K 2025-03-21] |
| 2025-05-09 | 30,307,313 | [10-Q 2025-05-09] |
| 2025-08-11 | 32,993,220 | [10-Q 2025-08-11] |
| 2025-11-07 | 37,032,307 | [10-Q 2025-11-07] |
| 2026-03-23 | 60,671,491 | [10-K 2026-03-23] |
| 2026-05-11 | 60,800,758 | [10-Q 2026-05-11] |
| 2026-08-10 | 60,825,844 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-09-25; declared effective 2026-10-06 [S-3 2026-09-25]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-14 | Vitoc Vlad | buy | 73,000 | $1.37 | [4 2026-09-15] |
| 2026-09-10 | Guerrero Ramiro | buy | 37,595 | $1.32 | [4 2026-09-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 424B3 | Prospectus or prospectus supplement |
| 2026-10-06 | 8-K | Regulation FD disclosure |
| 2026-10-02 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-25 | S-3 | Registration statement |
| 2026-08-21 | S-3 | Registration statement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-05-22 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 8-K | Material agreement terminated |
| 2026-05-14 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-11 | 10-Q | Quarterly report |
Alerts for $MAIA
Email me when MAIA Biotechnology, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.